Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC.

Frontiers in bioscience (Landmark edition) - 24 Jul 2023

Feng Huijing, Xu Huiru, Shi Xiuhuan, Ding Guobin, Yan Cihui, Li Linhan, Jian Zuoyi, Yang Xuejing, Guo Hongxia, Li Feng, Zhang Junping, Ren Xiubao

Abstract excerpt

BACKGROUND: Genetic mutations are quite common in non-small cell lung cancer (NSCLC), however, their prognostic value remains controversial. METHODS: This study explored the mutational landscape of tumor samples from patients with advanced NSCLC by next-generation sequencing (NGS). A total of 101 NSCLC patients in stage III or IV receiving first-line treatment were included. RESULTS: TP53 mutation was the most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Progression-Free Survival

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37525904
DOI: 10.31083/j.fbl2807147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC.PMID 37525904Read ↗

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).Semantic proximity Read ↗

TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study.Semantic proximity Read ↗

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.Semantic proximity Read ↗

TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapySemantic proximity Read ↗

Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.Semantic proximity Read ↗

The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.Semantic proximity Read ↗

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short ReviewSemantic proximity Read ↗

Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.Semantic proximity Read ↗

Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancerSemantic proximity Read ↗

Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome.Semantic proximity Read ↗

Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.